D9319C00001- 1L OC Mono Global RCT

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

May 31, 2021

Primary Completion Date

July 27, 2026

Study Completion Date

July 27, 2027

Conditions
Ovarian Cancer
Interventions
DRUG

Olaparib

Olaparib tablets 300 mg oral twice daily

OTHER

Matching placebo

Matching placebo tablets taken orally at a dose of 300 mg twice daily

Trial Locations (89)

27

Research Site, San Isidro

6045

Research Site, Port Elizabeth

11029

Research Site, New Delhi

14029

Research Site, Chernihiv

15036

Research Site, Lima

34010

Research Site, Istanbul

35575

Research Site, Karşıyaka

49102

Research Site, Dnipro

50030

Research Site, Medellín

50048

Research Site, Kryvyi Rih

55139

Research Site, Samsun

61103

Research Site, Kharkiv

76018

Research Site, Ivano-Frankivsk

100000

Research Site, Hanoi

Research Site, Hà Nội

100034

Research Site, Beijing

100142

Research Site, Beijing

110042

Research Site, Shenyang

110085

Research Site, New Delhi

110221

Research Site, Bogotá

115478

Research Site, Moscow

117997

Research Site, Moscow

122001

Research Site, Gūrgaon

130021

Research Site, Changchun

133000

Research Site, Yanji

163045

Research Site, Arkhangelsk

197758

Research Site, Saint Petersburg

198255

Research Site, Saint Petersburg

200011

Research Site, Shanghai

200032

Research Site, Shanghai

210009

Research Site, Nanjing

214062

Research Site, Wuxi

215004

Research Site, Suzhou

221000

Research Site, Xuzhou

221009

Research Site, Xuzhou

230001

Research Site, Hefei

230601

Research Site, Hefei

255200

Research Site, Zibo

266034

Research Site, Qingdao

272029

Research Site, Jining

276000

Research Site, Linyi

300050

Research Site, Tianjin

300060

Research Site, Tianjin

302017

Research Site, Jaipur

310022

Research Site, Hangzhou

314001

Research Site, Jiaxing

325027

Research Site, Wenzhou

325200

Research Site, Rui’an

400038

Research Site, Chongqing

400042

Research Site, Chongqing

410013

Research Site, Changsha

422002

Research Site, Nashik

430000

Research Site, Wuhan

430022

Research Site, Wuhan

454087

Research Site, Chelyabinsk

510095

Research Site, Guangzhou

510120

Research Site, Guangzhou

550004

Research Site, Guiyang

563100

Research Site, Zunyi

570311

Research Site, Haikou

610041

Research Site, Chengdu

610072

Research Site, Chengdu

620905

Research Site, Yekaterinburg

625107

Research Site, Madurai

634028

Research Site, Tomsk

637001

Research Site, Namakkal

700000

Research Site, Ho Chi Minh City

700160

Research Site, Kolkata

721008

Research Site, Baoji

730030

Research Site, Lanzhou

830000

Research Site, Ürümqi

830054

Research Site, Ürümqi

2540488

Research Site, Viña del Mar

4800827

Research Site, Temuco

4810218

Research Site, Temuco

8241479

Research Site, Santiago

8420383

Research Site, Santiago

CN-325000

Research Site, Wenzhou

Unknown

Research Site, Bogotá

Research Site, Zaporizhzhia

Research Site, Ho Chi Minh City

AREQUIPA01

Research Site, Arequipa

LIMA 29

Research Site, Lima

LIMA 34

Research Site, Lima

01120

Research Site, Adana

06100

Research Site, Ankara

06800

Research Site, Ankara

03022

Research Site, Kyiv

04050

Research Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY